Exelixis Net Worth
Exelixis Net Worth Breakdown | EXEL |
Exelixis Net Worth Analysis
Exelixis' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Exelixis' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Exelixis' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Exelixis' net worth analysis. One common approach is to calculate Exelixis' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Exelixis' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Exelixis' net worth. This approach calculates the present value of Exelixis' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Exelixis' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Exelixis' net worth. This involves comparing Exelixis' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Exelixis' net worth relative to its peers.
Enterprise Value |
|
To determine if Exelixis is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Exelixis' net worth research are outlined below:
| Exelixis has a strong financial position based on the latest SEC filings | |
| Over 92.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Exelixis Up 13.4 percent Since Last Earnings Report Can It Continue |
Exelixis Quarterly Good Will |
|
Exelixis uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Exelixis. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Exelixis' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 6th of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Exelixis Target Price Consensus
Exelixis target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Exelixis' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 22 | Buy |
Most Exelixis analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Exelixis stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Exelixis, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationExelixis Target Price Projection
Exelixis' current and average target prices are 36.65 and 34.47, respectively. The current price of Exelixis is the price at which Exelixis is currently trading. On the other hand, Exelixis' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On Exelixis Target Price
Know Exelixis' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Exelixis is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Exelixis backward and forwards among themselves. Exelixis' institutional investor refers to the entity that pools money to purchase Exelixis' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Nuveen Asset Management, Llc | 2024-12-31 | 3.5 M | Jpmorgan Chase & Co | 2024-12-31 | 3.3 M | Charles Schwab Investment Management Inc | 2024-12-31 | 3.3 M | Arrowstreet Capital Limited Partnership | 2024-12-31 | 3.2 M | Stephens Inv Mgmt Group Llc | 2024-12-31 | 3.1 M | Fmr Inc | 2024-12-31 | 2.9 M | Norges Bank | 2024-12-31 | 2.8 M | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 2.8 M | First Trust Advisors L.p. | 2024-12-31 | 2.5 M | Blackrock Inc | 2024-12-31 | 30.3 M | Vanguard Group Inc | 2024-12-31 | 29.4 M |
Follow Exelixis' market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 10.26 B.Market Cap |
|
Project Exelixis' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.18 | 0.09 | |
| Return On Capital Employed | 0.24 | 0.13 | |
| Return On Assets | 0.18 | 0.09 | |
| Return On Equity | 0.23 | 0.10 |
When accessing Exelixis' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Exelixis' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Exelixis' profitability and make more informed investment decisions.
Evaluate Exelixis' management efficiency
Exelixis has return on total asset (ROA) of 0.1464 % which means that it generated a profit of $0.1464 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2313 %, meaning that it created $0.2313 on every $100 dollars invested by stockholders. Exelixis' management efficiency ratios could be used to measure how well Exelixis manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to 0.09. The value of Return On Capital Employed is expected to slide to 0.13. At this time, Exelixis' Other Assets are quite stable compared to the past year. Net Tangible Assets is expected to rise to about 2.9 B this year, although the value of Return On Tangible Assets will most likely fall to 0.09.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 7.74 | 7.02 | |
| Tangible Book Value Per Share | 7.52 | 6.82 | |
| Enterprise Value Over EBITDA | 13.67 | 17.18 | |
| Price Book Value Ratio | 4.39 | 2.60 | |
| Enterprise Value Multiple | 13.67 | 17.18 | |
| Price Fair Value | 4.39 | 2.60 | |
| Enterprise Value | 1.2 B | 1.9 B |
Exelixis benefits from a proactive management team that anticipates market trends. Our analysis delves into how this proactive stance influences financial metrics and stock valuation.
Enterprise Value Revenue 4.3029 | Revenue | Quarterly Revenue Growth 0.182 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Exelixis insiders, such as employees or executives, is commonly permitted as long as it does not rely on Exelixis' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Exelixis insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Exelixis Corporate Filings
| 5th of March 2025 Other Reports | ViewVerify | |
F4 | 28th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 21st of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Exelixis Earnings Estimation Breakdown
The calculation of Exelixis' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Exelixis is estimated to be 0.4188 with the future projection ranging from a low of 0.29 to a high of 0.5471. Please be aware that this consensus of annual earnings estimates for Exelixis is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.29 Lowest | Expected EPS | 0.55 Highest |
Exelixis Earnings Projection Consensus
Suppose the current estimates of Exelixis' value are higher than the current market price of the Exelixis stock. In this case, investors may conclude that Exelixis is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Exelixis' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2025 | Current EPS (TTM) | |
| 22 | 76.08% | 0.55 | 0.4188 | 1.76 |
Exelixis Earnings History
Earnings estimate consensus by Exelixis analysts from Wall Street is used by the market to judge Exelixis' stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Exelixis' upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.Exelixis Quarterly Gross Profit |
|
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Exelixis' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Exelixis Earnings per Share Projection vs Actual
Actual Earning per Share of Exelixis refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Exelixis predict the company's earnings will be in the future. The higher the earnings per share of Exelixis, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Exelixis Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Exelixis, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Exelixis should always be considered in relation to other companies to make a more educated investment decision.Exelixis Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Exelixis' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-02-04 | 2024-12-31 | 0.4918 | 0.55 | 0.0582 | 11 | ||
2024-10-29 | 2024-09-30 | 0.35 | 0.4 | 0.05 | 14 | ||
2024-08-06 | 2024-06-30 | 0.3 | 0.77 | 0.47 | 156 | ||
2024-04-30 | 2024-03-31 | 0.24 | 0.2 | -0.04 | 16 | ||
2024-02-06 | 2023-12-31 | 0.21 | 0.27 | 0.06 | 28 | ||
2023-11-01 | 2023-09-30 | 0.1 | 0.1 | 0.0 | 0 | ||
2023-08-01 | 2023-06-30 | 0.16 | 0.25 | 0.09 | 56 | ||
2023-05-09 | 2023-03-31 | 0.15 | 0.12 | -0.03 | 20 | ||
2023-02-07 | 2022-12-31 | -0.12 | -0.09 | 0.03 | 25 | ||
2022-11-01 | 2022-09-30 | 0.19 | 0.23 | 0.04 | 21 | ||
2022-08-09 | 2022-06-30 | 0.19 | 0.22 | 0.03 | 15 | ||
2022-05-10 | 2022-03-31 | 0.14 | 0.21 | 0.07 | 50 | ||
2022-02-17 | 2021-12-31 | 0.06 | 0.29 | 0.23 | 383 | ||
2021-11-02 | 2021-09-30 | 0.17 | 0.12 | -0.05 | 29 | ||
2021-08-05 | 2021-06-30 | 0.06 | 0.3 | 0.24 | 400 | ||
2021-05-06 | 2021-03-31 | 0.03 | 0.005 | -0.025 | 83 | ||
2021-02-10 | 2020-12-31 | 0.05 | 0.09 | 0.04 | 80 | ||
2020-11-05 | 2020-09-30 | 0.01 | -0.1 | -0.11 | 1100 | ||
2020-08-06 | 2020-06-30 | 0.12 | 0.21 | 0.09 | 75 | ||
2020-05-05 | 2020-03-31 | 0.13 | 0.15 | 0.02 | 15 | ||
2020-02-25 | 2019-12-31 | 0.17 | 0.22 | 0.05 | 29 | ||
2019-10-30 | 2019-09-30 | 0.19 | 0.31 | 0.12 | 63 | ||
2019-07-31 | 2019-06-30 | 0.23 | 0.25 | 0.02 | 8 | ||
2019-05-01 | 2019-03-31 | 0.23 | 0.24 | 0.01 | 4 | ||
2019-02-12 | 2018-12-31 | 0.23 | 0.37 | 0.14 | 60 | ||
2018-11-01 | 2018-09-30 | 0.19 | 0.41 | 0.22 | 115 | ||
2018-08-01 | 2018-06-30 | 0.16 | 0.28 | 0.12 | 75 | ||
2018-05-02 | 2018-03-31 | 0.16 | 0.37 | 0.21 | 131 | ||
2018-02-26 | 2017-12-31 | 0.12 | 0.12 | 0.0 | 0 | ||
2017-11-01 | 2017-09-30 | 0.08 | 0.26 | 0.18 | 225 | ||
2017-08-02 | 2017-06-30 | 0.04 | 0.06 | 0.02 | 50 | ||
2017-05-01 | 2017-03-31 | -0.01 | 0.05 | 0.06 | 600 | ||
2017-02-27 | 2016-12-31 | -0.01 | 0.12 | 0.13 | 1300 | ||
2016-11-03 | 2016-09-30 | -0.11 | -0.04 | 0.07 | 63 | ||
2016-08-03 | 2016-06-30 | -0.27 | -0.16 | 0.11 | 40 | ||
2016-05-04 | 2016-03-31 | -0.25 | -0.27 | -0.02 | 8 | ||
2016-02-29 | 2015-12-31 | -0.22 | -0.19 | 0.03 | 13 | ||
2015-11-10 | 2015-09-30 | -0.2 | -0.22 | -0.02 | 10 | ||
2015-08-11 | 2015-06-30 | -0.21 | -0.22 | -0.01 | 4 | ||
2015-04-30 | 2015-03-31 | -0.24 | -0.18 | 0.06 | 25 | ||
2015-02-24 | 2014-12-31 | -0.3 | -0.3 | 0.0 | 0 | ||
2014-11-04 | 2014-09-30 | -0.37 | -0.32 | 0.05 | 13 | ||
2014-07-31 | 2014-06-30 | -0.39 | -0.38 | 0.01 | 2 | ||
2014-05-01 | 2014-03-31 | -0.37 | -0.39 | -0.02 | 5 | ||
2014-02-20 | 2013-12-31 | -0.38 | -0.38 | 0.0 | 0 | ||
2013-10-30 | 2013-09-30 | -0.37 | -0.36 | 0.01 | 2 | ||
2013-08-06 | 2013-06-30 | -0.3 | -0.34 | -0.04 | 13 | ||
2013-05-07 | 2013-03-31 | -0.28 | -0.24 | 0.04 | 14 | ||
2013-02-21 | 2012-12-31 | -0.24 | -0.28 | -0.04 | 16 | ||
2012-11-07 | 2012-09-30 | -0.3 | -0.2 | 0.1 | 33 | ||
2012-08-02 | 2012-06-30 | -0.27 | -0.25 | 0.02 | 7 | ||
2012-05-03 | 2012-03-31 | -0.17 | -0.18 | -0.01 | 5 | ||
2012-02-08 | 2011-12-31 | -0.11 | 0.35 | 0.46 | 418 | ||
2011-10-27 | 2011-09-30 | 0.56 | 0.59 | 0.03 | 5 | ||
2011-08-04 | 2011-06-30 | -0.17 | -0.16 | 0.01 | 5 | ||
2011-05-03 | 2011-03-31 | -0.19 | -0.24 | -0.05 | 26 | ||
2011-02-22 | 2010-12-31 | -0.2 | -0.16 | 0.04 | 20 | ||
2010-11-04 | 2010-09-30 | -0.05 | -0.08 | -0.03 | 60 | ||
2010-08-05 | 2010-06-30 | -0.21 | -0.21 | 0.0 | 0 | ||
2010-05-11 | 2010-03-31 | -0.31 | -0.4 | -0.09 | 29 | ||
2010-03-09 | 2009-12-31 | -0.27 | -0.27 | 0.0 | 0 | ||
2009-10-29 | 2009-09-30 | -0.32 | -0.24 | 0.08 | 25 | ||
2009-07-30 | 2009-06-30 | -0.41 | -0.42 | -0.01 | 2 | ||
2009-05-07 | 2009-03-31 | -0.33 | -0.34 | -0.01 | 3 | ||
2009-03-04 | 2008-12-31 | -0.35 | -0.36 | -0.01 | 2 | ||
2008-10-27 | 2008-09-30 | -0.41 | -0.36 | 0.05 | 12 | ||
2008-08-05 | 2008-06-30 | -0.41 | -0.43 | -0.02 | 4 | ||
2008-05-06 | 2008-03-31 | -0.38 | -0.39 | -0.01 | 2 | ||
2008-02-14 | 2007-12-31 | -0.29 | -0.19 | 0.1 | 34 | ||
2007-11-05 | 2007-09-30 | -0.19 | -0.14 | 0.05 | 26 | ||
2007-08-07 | 2007-06-30 | -0.28 | -0.29 | -0.01 | 3 | ||
2007-05-03 | 2007-03-31 | -0.27 | -0.25 | 0.02 | 7 | ||
2007-02-13 | 2006-12-31 | -0.25 | -0.27 | -0.02 | 8 | ||
2006-11-02 | 2006-09-30 | -0.31 | -0.3 | 0.01 | 3 | ||
2006-08-08 | 2006-06-30 | -0.3 | -0.29 | 0.01 | 3 | ||
2006-05-09 | 2006-03-31 | -0.29 | -0.32 | -0.03 | 10 | ||
2006-02-21 | 2005-12-31 | -0.28 | -0.29 | -0.01 | 3 | ||
2005-11-03 | 2005-09-30 | -0.39 | -0.28 | 0.11 | 28 | ||
2005-08-08 | 2005-06-30 | -0.05 | -0.13 | -0.08 | 160 | ||
2005-05-09 | 2005-03-31 | -0.36 | -0.36 | 0.0 | 0 | ||
2005-02-16 | 2004-12-31 | -0.38 | -0.35 | 0.03 | 7 | ||
2004-11-08 | 2004-09-30 | -0.42 | -0.37 | 0.05 | 11 | ||
2004-08-05 | 2004-06-30 | -0.38 | -0.37 | 0.01 | 2 | ||
2004-05-04 | 2004-03-31 | -0.41 | -0.39 | 0.02 | 4 | ||
2004-02-17 | 2003-12-31 | -0.35 | -0.32 | 0.03 | 8 | ||
2003-11-05 | 2003-09-30 | -0.38 | -0.34 | 0.04 | 10 | ||
2003-08-06 | 2003-06-30 | -0.42 | -0.4 | 0.02 | 4 | ||
2003-05-07 | 2003-03-31 | -0.41 | -0.38 | 0.03 | 7 | ||
2003-02-19 | 2002-12-31 | -0.4 | -0.34 | 0.06 | 15 | ||
2002-11-07 | 2002-09-30 | -0.42 | -0.39 | 0.03 | 7 | ||
2002-08-06 | 2002-06-30 | -0.41 | -0.39 | 0.02 | 4 | ||
2002-05-06 | 2002-03-31 | -0.31 | -0.31 | 0.0 | 0 | ||
2002-03-20 | 2001-12-31 | -0.32 | -0.26 | 0.06 | 18 | ||
2001-11-13 | 2001-09-30 | -0.31 | -0.28 | 0.03 | 9 | ||
2001-08-08 | 2001-06-30 | -0.31 | -0.3 | 0.01 | 3 | ||
2001-05-14 | 2001-03-31 | -0.26 | -0.22 | 0.04 | 15 | ||
2001-02-28 | 2000-12-31 | -0.2 | -0.18 | 0.02 | 10 | ||
2000-11-08 | 2000-09-30 | -0.13 | -0.13 | 0.0 | 0 | ||
2000-08-08 | 2000-06-30 | -0.13 | -0.16 | -0.03 | 23 |
Exelixis Corporate Management
| Amy MD | Product VP | Profile | |
| Laura Dillard | Executive Resources | Profile | |
| Tony Redmond | Senior Resources | Profile | |
| Gregg Bernier | VP Marketing | Profile | |
| William MD | Senior Affairs | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Exelixis. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy Exelixis Stock please use our How to buy in Exelixis Stock guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exelixis. If investors know Exelixis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exelixis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.754 | Earnings Share 1.76 | Revenue Per Share | Quarterly Revenue Growth 0.182 | Return On Assets |
The market value of Exelixis is measured differently than its book value, which is the value of Exelixis that is recorded on the company's balance sheet. Investors also form their own opinion of Exelixis' value that differs from its market value or its book value, called intrinsic value, which is Exelixis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exelixis' market value can be influenced by many factors that don't directly affect Exelixis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exelixis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Exelixis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exelixis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.